Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL Gravina, F Marampon, I Giusti… - International …, 2012 - spandidos-publications.com
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …
被引用次数：49 相关文章
[PDF] archive.org

[PDF][PDF] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL GRAVINA, F MARAMPON, I GIUSTI… - INTERNATIONAL …, 2012 - scholar.archive.org
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL Gravina, F Marampon, I Giusti… - International …, 2012 - spandidos-publications.com
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL Gravina, F Marampon, I Giusti, E Carosa… - INTERNATIONAL …, 2012 - iris.uniroma1.it
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …
[PDF] researchgate.net

[PDF][PDF] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL GRAVINA, F MARAMPON, I GIUSTI… - INTERNATIONAL …, 2012 - researchgate.net
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

[引用][C] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

G LUCA GRAVINA, F MARAMPON… - … journal of oncology, 2012 - pascal-francis.inist.fr
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent
prostate cancer models CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

GL Gravina, F Marampon, I Giusti, E Carosa… - … Journal of Oncology, 2011 - europepmc.org
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …
[PDF] academia.edu

[PDF][PDF] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL GRAVINA, F MARAMPON, I GIUSTI… - INTERNATIONAL …, 2012 - academia.edu
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

GL Gravina, F Marampon, I Giusti… - … journal of oncology, 2012 - pubmed.ncbi.nlm.nih.gov
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models

D Sante - International Journal of Oncology, 2012 - ingentaconnect.com
Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics
rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the …